Renaissance Technologies
KALV

Renaissance Technologies’s KalVista Pharmaceuticals KALV Stock Holding History

Renaissance Technologies’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-165,151
Closed -$2.67M – 3487
2025
Q4 		$2.67M Buy
+165,151
New +$2.19M ﹤0.01% 1689
2024
Q2 		– Sell
-243,484
Closed -$2.89M – 3752
2024
Q1 		$2.89M Buy
243,484
+201,184
+476% +$2.68M ﹤0.01% 1790
2023
Q4 		$518K Sell
42,300
-26,800
-39% -$244K ﹤0.01% 2750
2023
Q3 		$665K Sell
69,100
-73,828
-52% -$754K ﹤0.01% 2570
2023
Q2 		$1.29M Buy
142,928
+62,328
+77% +$575K ﹤0.01% 2310
2023
Q1 		$634K Sell
80,600
-13,700
-15% -$102K ﹤0.01% 2756
2022
Q4 		$637K Sell
94,300
-29,800
-24% -$160K ﹤0.01% 2804
2022
Q3 		$1.8M Sell
124,100
-105,270
-46% -$1.47M ﹤0.01% 2081
2022
Q2 		$2.26M Buy
229,370
+212,570
+1,265% +$2.34M ﹤0.01% 2103
2022
Q1 		$248K Sell
16,800
-5,627
-25% -$80.8K ﹤0.01% 3552
2021
Q4 		$297K Sell
22,427
-1,101
-5% -$17.5K ﹤0.01% 3347
2021
Q3 		$411K Buy
+23,528
New +$477K ﹤0.01% 2960
2021
Q2 		– Sell
-153,428
Closed -$3.94M – 3633
2021
Q1 		$3.94M Buy
153,428
+104,000
+210% +$2.73M ﹤0.01% 1800
2020
Q4 		$939K Buy
+49,428
New +$848K ﹤0.01% 2528
2020
Q3 		– Sell
-41,346
Closed -$500K – 3524
2020
Q2 		$500K Sell
41,346
-6,182
-13% -$65.7K ﹤0.01% 2876
2020
Q1 		$364K Buy
+47,528
New +$641K ﹤0.01% 2900
2019
Q4 		– Sell
-19,028
Closed -$221K – 3627
2019
Q3 		$221K Buy
+19,028
New +$307K ﹤0.01% 3119
2019
Q2 		– Sell
-159,929
Closed -$4.58M – 3655
2019
Q1 		$4.58M Sell
159,929
-19,300
-11% -$418K ﹤0.01% 1859
2018
Q4 		$3.54M Buy
179,229
+61,880
+53% +$1.24M ﹤0.01% 1948
2018
Q3 		$2.6M Buy
117,349
+81,621
+228% +$1.1M ﹤0.01% 2154
2018
Q2 		$290K Sell
35,728
-7,700
-18% -$68K ﹤0.01% 2973
2018
Q1 		$412K Sell
43,428
-45,300
-51% -$474K ﹤0.01% 2972
2017
Q4 		$865K Buy
+88,728
New +$923K ﹤0.01% 2721
2016
Q4 		– Sell
-17,337
Closed -$112K – 3350
2016
Q3 		$112K Buy
+17,337
New +$131K ﹤0.01% 3164

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies's KALV Position: Q1 2026 in Review

Renaissance Technologies sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 165,151 shares — an estimated $2.67M sold.

Renaissance Technologies first reported a position in KALV in Q3 2016 and held it in 24 quarters. The position peaked at $4.58M in Q1 2019. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Renaissance Technologies reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Renaissance Technologies sold 165,151 KalVista Pharmaceuticals shares in Q1 2026, an estimated $2.67M.
  • Renaissance Technologies first reported a position in KalVista Pharmaceuticals in Q3 2016 and held it in 24 quarters.
  • Renaissance Technologies's KalVista Pharmaceuticals position peaked at $4.58M in Q1 2019.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.